prostatepedia magazine covers

 

Prostatepedia features informal conversations with doctors, patients, and activists about prostate cancer about prostate cancer. Each month they tackle a different topic facing prostate cancer patients today—from how imaging has impacted treatment to dealing with erectile dysfunction after radiation or surgery to the evolving field of immunotherapy.

Prostatepedia Magazine (quarterly) and the weekly Prostatepedia Digests are now part of NASPCC, beginning with this month's August magazine issue.

Use this link to learn more about Prostatepedia...

NASPCC logoHere is information about recent NASPCC webinars. Use the links below to view the recorded webinar and handouts:

“The PROCEED Registry and Disparities Work in Metastatic Prostate Cancer”

With Dr. Andrew Armstrong, Professor of Medicine, Surgery, Pharmacology and Cancer Biology and Director of Research, the Duke Cancer Institute Center for Prostate and Urologic Cancers at Duke University.

Recorded: Wednesday, November 4, 2020

About the Presenter

Dr. Andrew Armstrong is a tenured Professor of Medicine, Surgery, Pharmacology and Cancer Biology and Director of Research for the Duke Cancer Institute’s Center for Prostate and Urologic Cancer. He is a medical oncologist and internationally recognized expert in experimental therapeutics and biomarker development in genitourinary cancers, particularly in prostate cancer. He trained at Duke as a biomedical engineer, received his medical degree at the University of Virginia, medicine residency training at the University of Pennsylvania, fellowship and public health clinical investigation training at Johns Hopkins and the Bloomberg School of Public Health, and joined Duke’s faculty in 2006.

Dr. Armstrong has developed a number of experimental agents in prostate and renal cell cancer, including completed or ongoing trials of AR inhibitors, immunotherapies, mTOR/PI3K inhibitors, and anti-angiogenic agents, and is heavily involved in the leadership of multiple ongoing phase 1-4 treatment and biomarker trials in men with advanced prostate cancer including serving as correlative science chair within the NCI ALLIANCE Cooperative Group in the GU Committee. He has authored over 170 peer reviewed publications as well as numerous chapters, reviews, and abstracts. He leads a team of over 50 research nurses, coordinators, data managers, regulatory specialists, scientists, and investigators dedicated to discovery science in GU cancers in the laboratory and treatment science in the clinic. As an R01 funded clinical-translational investigator, he has mentored over a dozen medical oncology fellows and junior faculty, and many residents and students both in the clinical, for clinical trials, and for laboratory training.

Resources

 

Sponsor

NASPCC is receiving support for this webinar from Dendreon:

Dendron: Targeting Cancer, Transforming Lives logo


“Immunotherapy and PARP Inhibition”

With Dr. Judd Moul, Professor, Duke University Medical Center.

Recorded: October 5, 2020

About the Presenter

Judd W Moul, MD, FACS is the James H Semans MD Professor of Surgery at Duke University. In 2004, after completing a 26-year U.S. Army career and retiring as full Colonel in the Medical Corps, Moul became Chief of the Division of Urologic Surgery at Duke. Serving as Chief until 2011, he established the Duke Prostate Center (DPC) and directed the development of a DPC Outcomes database that contained the records of over 10,000 prostate cancer patients.

Dr. Moul serves on the editorial boards of American Journal of Men’s Health, Urology and Prostate Cancer and Prostatic Diseases. He serves on the Executive Committee for the American Joint Commission for Cancer (AJCC). Dr. Moul has published over 600 medical and scientific manuscripts and book chapters and has lectured at national and international meetings. He has been a visiting professor and invited guest lecturer at universities and national symposia, in addition to appearances on ABC, NBC, CNN, PBS, and other media as a prostate cancer authority. Honors and awards received have included the American Medical Association’s Young Physicians Section Community Service Award, the Sir Henry Welcome Research Medal and Prize from the Association of Military Surgeons of the United States, the Gold Cystoscope Award by the American Urological Association, the Baron Dominique Jean Larrey Military Surgeon Award for Excellence, the Order of Military Medical Merit from the Surgeon General of the US Army, and the Castle Connolly National Physician of the Year award in 2009. *Dr. Judd Moul is not receiving any compensation for this presentation*

Resources

Sponsor 

NASPCC is receiving support for this Webinar from Dendron:

Dendron: Targeting Cancer, Transforming Lives logo

 


“PSMA Imaging in Prostate Cancer: New Developments”

With Dr. Michael Morris, Clinical Director, Memorial Sloan-Kettering Cancer Center in New York

Recorded: October 1, 2020

About the Presenter

Dr. Michael Morris is prostate cancer specialist, clinical investigator, and the Section Head of Prostate Cancer of the Genitourinary Oncology Service at Memorial Sloan-Kettering Cancer Center. He earned his medical degree from the Mount Sinai School of Medicine in New York, and performed his internship and residency in Internal Medicine at Columbia Presbyterian Medical Center. He then completed his medical oncology fellowship at Memorial Sloan-Kettering Cancer Center, where he was the Chief Fellow as well.

Dr. Morris has led numerous clinical trials, but he has a particular research focus on targeted therapy for prostate cancer, especially those that bridge the fields of Medical Oncology and Nuclear Medicine. In the field of therapeutics, he has focused on radio immunotherapy and other radio-conjugates, bone directed therapy, and other targeted therapies. In the field of diagnostics, he has a keen research interest in developing novel imaging technologies for metastatic prostate cancer and in developing novel imaging biomarkers. He has been a co-developer of the Prostate Cancer Working Group 2 and 3 Consensus Criteria, and novel prostate-specific imaging technologies such as FDHT PET and PSMA-directed PET imaging.

In addition, he is the Medical Director of the Department of Prostate Cancer Clinical Consortium, and chairs the GU Committee of the Alliance for Oncology Trials in Oncology (formerly CALGB).

Resources

Sponsor

This Webinar is sponsored by: Progenics Pharmaceuticals

Progenics Pharmaceuticals: Find Fight and Follow

 


“Exosome Testing and Liquid Biopsies – Risk Assessment for High-Grade Prostate Cancer: Home or Office Testing”

With Dr. Judd Moul, Professor, Duke University Medical Center.

Recorded: July 29, 2020

About the Presenter

Judd W Moul, MD, FACS is the James H Semans MD Professor of Surgery at Duke University. In 2004, after completing a 26-year U.S. Army career and retiring as full Colonel in the Medical Corps, Moul became Chief of the Division of Urologic Surgery at Duke. Serving as Chief until 2011, he established the Duke Prostate Center (DPC) and directed the development of a DPC Outcomes database that contained the records of over 10,000 prostate cancer patients.

Resources

Sponsor

This Webinar is sponsored by: Exosome Diagnostics

ExosomeDx: A biotechme brand - logo


 

Managing the Side Effects of Prostate Cancer and its Treatment: Emotional Distress, Intimacy Issues, Erectile Dysfunction and Incontinence

Recorded February 27, 2020

Sponsored by Boston Scientific.

Presenters

Dr. Krishnan Venkatesan, MD
Director of Urologic Reconstruction, Washington Hospital Center.

A native of Detroit, Dr. Krishnan completed his undergraduate studies at Columbia University in the City of New York before returning home for medical school at Wayne State University. He stayed on at Wayne State for his residency in Urology,which he completed in 2010. He then undertook a fellowship in Genitourinary Reconstruction at the Institute of Urology at University College London and went on to Pune, India to pursue further training in complex urethral reconstruction at the Kulkarni EndoSurgery Institute. Krishnan then moved to Washington, DC to become the Director of Urologic Reconstruction at MedStar Washington Hospital Center, a 900-bed urban tertiary care and trauma center. He is an Associate Professor in the Georgetown University Department of Urology and participates actively in resident training. Over his 7 years in Washington, he has developed the Reconstructive Unit into a referral center for complex genitourinary reconstruction and prosthetics throughout the Mid-Atlantic Region. He has had his work presented at the regional, national and international level, and has co-authored a number of publications in the urologic reconstruction subspecialty.

William Goeren, MSW, OSW-C, LCSW-R
Clinical Program Director,CancerCare, New York.

Bill Goren is the Director of Clinical Programs at CancerCare. Prior to his work at CancerCare, William was the Director of Mental Health for the AIDS Healthcare Foundation in Los Angeles, and, in 1994, opened the first Gilda’s Club in New York City. He is the co-author of the chapter “Unique Issues Confronting Gay, Lesbian, and Bisexual Individuals Diagnosed with Cancer” for the Oxford University Press Handbook of Oncology Social Work and the author of the chapter Social Work, HIV Disease, and Palliative Care” for the Oxford Textbook of Palliative Social Work.

Resources


Webinar: Genetic Testing and Genetic Counseling in Prostate Cancer

Recorded May 09, 2018

Sponsored by Myriad Genetics

Dr. Leonard G. Gomella, Chair of the Urology Department at the Kimmel Cancer Center Network of Jefferson Medical College will be presenting on "Genetic Testing and Genetic Counseling in Prostate Cancer".

Resources

Determine your hereditary cancer risk

Myriad Genetics is offering a free heredity cancer quiz. This brief questionnaire will help you determine whether you should be further evaluated for Hereditary Breast and Ovarian Cancer syndrome, Lynch syndrome, or other hereditary cancers:

Use this link to access the free heredity cancer quiz...


AR-V7 Splice Variant and Treatment Choices in Prostate Cancer

Recorded - April 3, 2018 with Ryan Dittamore and Deb Davison

Ryan Dittamore of Epic Sciences and Deb Davison from Genomic Health present on “AR-V7 Splice Variant and Treatment Choices in Prostate Cancer.”

This webinar was provided through a generous donation from Genomic Health


Tissue Based Biomarkers for Localized Prostate Cancer

January 30, 2018 - with Dr. Ashley Ross, M.D., Ph.D.

Dr. Ross' presentation was provided through a generous donation from Genomic Health

 

 

 

rev: 10/08/2020